Study limitation: ARTIOS is a single-arm study sponsored by Novartis (ofatumumab's manufacturer); several co-authors are Novartis employees, which introduces potential industry bias | ReachRx
Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study
Study limitation reported by the research below: “ARTIOS is a single-arm study sponsored by Novartis (ofatumumab's manufacturer); several co-authors are Novartis employees, which introduces potential industry bias.”
